Evaxion Biotech A/S
EVAX
View Detailed Chart
3.020USD
+0.095+3.25%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
953.80MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.25%
5 Days
+4.86%
1 Month
-6.21%
6 Months
+63.24%
Year to Date
-28.55%
1 Year
-80.64%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.000
Target Price
+240.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.34M.
Undervalued
The company’s latest PE is -5.74, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.59M shares, increasing 44.92% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Ticker SymbolEVAX
CompanyEvaxion Biotech A/S
CEO
Websitehttps://evaxion.ai/
Related Instruments
-0.35%
-4.12%
+3.22%
+1.88%
+0.75%
-1.87%
+0.72%
+6.30%
+0.83%
+2.41%
-0.11%
+0.02%
+2.31%
+0.70%
+2.93%
+0.93%
+5.59%
+3.22%
0.00%
+2.85%
